0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Other Articles |

BENZEDRINE SULFATE—A WARNING

JAMA. 1938;110(12):901-902. doi:10.1001/jama.1938.02790120043013.
Text Size: A A A
Published online

Following the appearance of items in the press duringe last few weeks, many inquiries have been received concerning the use of benzedrine suflage in the treatment of obesity. Sensational reports on the effects of benzedrine sulfate are not new to the medical press or to the daily newspapers. Some months ago The Journal published a critical editorial on benzedrine sulfate.1 At that time the drug was being used unwisely to avoid fatigue; news that it could be obtained for keeping one awake while "cramming" for final examinations spread from campus to campus. The drug has been employed for such widely variable conditions as anginal pain, seasickness and apathy. Now it is suggested for weight reduction. While not as toxic as the ill famed reducing agent dinitrophenol,2 nevertheless its use may be followed by serious consequences. Just as the Council on Pharmacy and Chemistry issued a report on the status of dinitrophenol, it has recently published a report on benzeddrine sulfate.3

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();